Home › Calculator › SYRS Dividend Calculator 2026
SYRS Dividend DRIP Calculator 2026
500000.00% YieldHealthcareSyros Pharmaceuticals, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When SYRS pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your SYRS snowball 📈
$10,000 in SYRS → $2.2713206875858523e+46M in 10 years · $1,892,766,111,821,283,400,000,000,000,000,000,000,000,000,000,000,000.00/month
About Syros Pharmaceuticals, Inc. (SYRS) — Dividend Analysis 2026
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.
Compare SYRS with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full SYRS DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SYRS position with:
🌍 SYRS Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SYRS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 500000.00% | 499997.20% | $50,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 425000.00% | 424997.20% | $42,500,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 400000.00% | 399997.20% | $40,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 500000.00% | 499997.20% | $50,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 456250.00% | 456247.20% | $45,625,000 / yr |
| 🇨🇦 TFSA | 0% | 500000.00% | 499997.20% | $50,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 375000.00% | 374997.20% | $37,500,000 / yr |
| 🇦🇺 Super (pension) | 15% | 425000.00% | 424997.20% | $42,500,000 / yr |
| 🇦🇺 AU Taxable | 30% | 350000.00% | 349997.20% | $35,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 368125.00% | 368122.20% | $36,812,500 / yr |
| 🇫🇷 FR Taxable | 30% | 350000.00% | 349997.20% | $35,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SYRS Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SYRS Dividend Payment Schedule
SYRS pays quarterly — 4 times per year. Next ex-div: TBD.
📊 SYRS vs Healthcare Benchmarks
How SYRS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SYRS sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SYRS Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SYRS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Syros Pharmaceuticals, Inc. (SYRS) is currently trading at $0.00, 100% below its 52-week high. The current dividend yield is 500000.00% based on an annual payout of $2.00 per share.
SYRS (Syros Pharmaceuticals, Inc.) — 500000.00% Dividend Yield Analysis
Syros Pharmaceuticals, Inc. (SYRS) is a healthcare stock currently trading at $0.00 with a dividend yield of 500000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (500000.00%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.